Sector Update: Health Care Stocks Mixed Premarket Tuesday

MT Newswires Live06-11

Health care stocks were mixed premarket Tuesday, with the Health Care Select Sector SPDR Fund (XLV) was 0.1% higher and the iShares Biotechnology ETF (IBB) was down 0.5% recently.

Viridian Therapeutics (VRDN) advanced more than 6% after saying it will begin two late-stage clinical trials to evaluate VRDN-003 in patients with active and chronic thyroid eye disease in August.

ProKidney (PROK) was down more than 15% after it launched an underwritten public offering and a concurrent registered direct offering of up to $125 million of its class A shares.

Arcutis Biotherapeutics (ARQT) was more than 2% higher after saying its experimental roflumilast cream 0.15% showed continued improvements in the signs and symptoms of atopic dermatitis, including itch, through 56 weeks of treatment.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2442539620?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-06-11 21:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2442539620","market":"hk","top_or_hot":-1,"title":"Sector Update: Health Care Stocks Mixed Premarket Tuesday","media":"MT Newswires Live","content":"<html><body><p> Health care stocks were mixed premarket Tuesday, with the Health Care Select Sector SPDR Fund (XLV) was 0.1% higher and the <a href=\"https://laohu8.com/S/EEMA\">iShares</a> Biotechnology ETF (IBB) was down 0.5% recently. </p><p>Viridian <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (VRDN) advanced more than 6% after saying it will begin two late-stage clinical trials to evaluate VRDN-003 in patients with active and chronic thyroid eye disease in August.</p><p>ProKidney (PROK) was down more than 15% after it launched an underwritten public offering and a concurrent registered direct offering of up to $125 million of its class A shares.</p><p>Arcutis Biotherapeutics (ARQT) was more than 2% higher after saying its experimental roflumilast cream 0.15% showed continued improvements in the signs and symptoms of atopic dermatitis, including itch, through 56 weeks of treatment.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sector Update: Health Care Stocks Mixed Premarket Tuesday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSector Update: Health Care Stocks Mixed Premarket Tuesday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-11 21:11 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Health care stocks were mixed premarket Tuesday, with the Health Care Select Sector SPDR Fund (XLV) was 0.1% higher and the iShares Biotechnology ETF (IBB) was down 0.5% recently. Viridian ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"XLV","symbol_name":"健康照护类股ETF-SPDR","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2442539620","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2442539620","pubTimestamp":1718111491,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Health care stocks were mixed premarket Tuesday, with the Health Care Select Sector SPDR Fund  was 0.1% higher and the iShares Biotechnology ETF  was down 0.5% recently. Viridian Therapeutics  advanced more than 6% after saying it will begin two late-stage clinical trials to evaluate VRDN-003 in patients with active and chronic thyroid eye disease in August.ProKidney  was down more than 15% after it launched an underwritten public offering and a concurrent registered direct offering of up to $125 million of its class A shares.Arcutis Biotherapeutics  was more than 2% higher after saying its experimental roflumilast cream 0.15% showed continued improvements in the signs and symptoms of atopic dermatitis, including itch, through 56 weeks of treatment.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"XLV":"健康照护类股ETF-SPDR","VRDN":"Viridian Therapeutics, Inc.","BK4585":"ETF&股票定投概念","BK4139":"生物科技","BK4581":"高盛持仓","BK4588":"碎股","IBB":"生物科技指数ETF-iShares Nasdaq","ARQT":"Arcutis Biotherapeutics Inc.","PROK":"ProKidney Corp."},"translate_title":"行业更新：医疗保健股周二盘前涨跌互现","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARQT":0.9,"IBB":0.9,"PROK":0.9,"VRDN":0.9,"XLV":0.9},"content_text":"Health care stocks were mixed premarket Tuesday, with the Health Care Select Sector SPDR Fund (XLV) was 0.1% higher and the iShares Biotechnology ETF (IBB) was down 0.5% recently. Viridian Therapeutics (VRDN) advanced more than 6% after saying it will begin two late-stage clinical trials to evaluate VRDN-003 in patients with active and chronic thyroid eye disease in August.ProKidney (PROK) was down more than 15% after it launched an underwritten public offering and a concurrent registered direct offering of up to $125 million of its class A shares.Arcutis Biotherapeutics (ARQT) was more than 2% higher after saying its experimental roflumilast cream 0.15% showed continued improvements in the signs and symptoms of atopic dermatitis, including itch, through 56 weeks of treatment.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2442539620"}